References
- 1. Mutnick AH, Rhomberg PR, Sader HS, Jones RN. Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001). J Antimicrob Chemother. 2004; 53:290-6.
- 2. Barradell LB, Bryson HM. Cefepime: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1994; 47:471-505.10.2165/00003495-199447030-00007
- 3. Yahav D, Paul M, Fraser A, Sarid N, Leibovici L. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis. 2007; 7:338-48.10.1016/S1473-3099(07)70109-3
- 4. Barbhaiya RH, Forgue ST, Shyu WC, Papp EA, Pittman KA. High-pressure liquid chromatographic analysis of BMY-28142 in plasma and urine. Antimicrob Agents Chemother. 1987; 31:55-9.
- 5. Barbhaiya RH, Fougue ST, Gleason CR, Knupp CA, Pittman KA, Weidler DJ, et al. Safety tolerance and pharmacokinetic evaluation of cefepime after administration of single intravenous doses. Antimicrob Agents Chemother. 1990; 34:1118-22.
- 6. Barbhaiya RH, Knupp CA, Tenny J, Martin RR, Weidler DJ, Pittman KA. Safety tolerance and pharmacokinetic of cefepime administered intramuscularly to healthy subjects. J Clin Pharmacol. 1990; 30:900-10.1002/j.1552-4604.1990.tb03569.x